Can Lumbar Spine Bone Mineral Density Predict Readmission in Denosumab-treated Patients with Chronic Kidney Disease?

Overview

Journal J Investig Med

Publisher Sage Publications

Specialty General Medicine

Date 2016 Sep 2

PMID 27581054

Citations 1

Authors

Ben-Chung Cheng

Ying-Chou Chen

Affiliations

Soon will be listed here.

Abstract

This study investigated whether bone mineral density (BMD) affects readmission risk in patients with chronic kidney diseases (CKD) who received denosumab therapy. The study design was a retrospective case review of patients with CKD. Baseline age, sex, and body mass index were recorded for all patients included in the study. All comorbidities were recorded. All subjects underwent dual energy X-ray absorptiometry assay of the lumbar spine and right hip for BMD. The primary outcome was readmission. Predictive variables were categorized and compared between readmitted and non-readmitted patients. Logistic regression was used for multivariable analysis. A total of 121 patients with CKD who received denosumab therapy were enrolled. Of these, 29 were readmitted within 2 years, and 92 had no readmission. The lumbar BMD differed between the readmission (-2.94±0.68) and non-readmission (-2.09±1.48) groups. The readmission group had a lower T score than the non-readmission group. When adjusted for potential confounding factors, a decreased lumbar BMD had a higher readmission risk. When the cut-off points determined by receiver operating characteristic curve analysis were applied, the most precise point was set at a T score of -3. Osteoporosis in patients with CKD is associated with a high risk of readmission; the best predictor after denosumab therapy was the lumbar spine T score. A lower T score (especially if <-3) was associated with a higher probability of fracture readmission. It is essential to optimize primary and secondary prevention in these patients to improve their quality of life.

Citing Articles

Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies.

Thongprayoon C, Acharya P, Acharya C, Chenbhanich J, Bathini T, Boonpheng B Osteoporos Int. 2018; 29(8):1737-1745.

PMID: 29713798 DOI: 10.1007/s00198-018-4533-6.

References

Cunningham J, Sprague S, Cannata-Andia J, Coco M, Cohen-Solal M, Fitzpatrick L . Osteoporosis in chronic kidney disease. Am J Kidney Dis. 2004; 43(3):566-71. DOI: 10.1053/j.ajkd.2003.12.004. View

Stehman-Breen C, Sherrard D, Alem A, Gillen D, Heckbert S, Wong C . Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int. 2000; 58(5):2200-5. DOI: 10.1111/j.1523-1755.2000.00394.x. View

Lau E, Ong K, Kurtz S, Schmier J, Edidin A . Mortality following the diagnosis of a vertebral compression fracture in the Medicare population. J Bone Joint Surg Am. 2008; 90(7):1479-86. DOI: 10.2106/JBJS.G.00675. View

Alem A, Sherrard D, Gillen D, Weiss N, Beresford S, Heckbert S . Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 2000; 58(1):396-9. DOI: 10.1046/j.1523-1755.2000.00178.x. View

Boyle W, Simonet W, Lacey D . Osteoclast differentiation and activation. Nature. 2003; 423(6937):337-42. DOI: 10.1038/nature01658. View

Kanis J, Seeman E, Johnell O, Rizzoli R, Delmas P . The perspective of the international osteoporosis foundation on the official positions of the international society for clinical densitometry. J Clin Densitom. 2005; 8(2):145-7. DOI: 10.1385/jcd:8:2:145. View

Bone H, Bolognese M, Yuen C, Kendler D, Wang H, Liu Y . Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab. 2008; 93(6):2149-57. DOI: 10.1210/jc.2007-2814. View

Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K . Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006; 69(11):1945-53. DOI: 10.1038/sj.ki.5000414. View

Chen Y, Yang Y, Wang S, Chou W, Chiu P, Lin C . Multidisciplinary care improves clinical outcome and reduces medical costs for pre-end-stage renal disease in Taiwan. Nephrology (Carlton). 2014; 19(11):699-707. PMC: 4265277. DOI: 10.1111/nep.12316. View

10.

van Geel T, van Helden S, Geusens P, Winkens B, Dinant G . Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis. 2008; 68(1):99-102. DOI: 10.1136/ard.2008.092775. View

11.

Lacey D, Boyle W, Simonet W, Kostenuik P, Dougall W, Sullivan J . Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 2012; 11(5):401-19. DOI: 10.1038/nrd3705. View

12.

Kostenuik P, Nguyen H, McCabe J, Warmington K, Kurahara C, Sun N . Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res. 2008; 24(2):182-95. DOI: 10.1359/jbmr.081112. View

13.

Gabay C, Ruedin P, Slosman D, Bonjour J, LESKI M, Rizzoli R . Bone mineral density in patients with end-stage renal failure. Am J Nephrol. 1993; 13(2):115-23. DOI: 10.1159/000168600. View

14.

Puisto V, Rissanen H, Heliovaara M, Knekt P, Helenius I . Mortality in the presence of a vertebral fracture, scoliosis, or Scheuermann's disease in the thoracic spine. Ann Epidemiol. 2008; 18(8):595-601. DOI: 10.1016/j.annepidem.2008.04.009. View

15.

Gal-Moscovici A, Sprague S . Osteoporosis and chronic kidney disease. Semin Dial. 2007; 20(5):423-30. DOI: 10.1111/j.1525-139X.2007.00319.x. View

16.

Yamaguchi T, Kanno E, Tsubota J, Shiomi T, Nakai M, Hattori S . Retrospective study on the usefulness of radius and lumbar bone density in the separation of hemodialysis patients with fractures from those without fractures. Bone. 1996; 19(5):549-55. DOI: 10.1016/s8756-3282(96)00246-3. View

17.

Delmas P . Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases. J Clin Densitom. 2008; 11(2):325-38. DOI: 10.1016/j.jocd.2008.02.002. View

18.

McClung M, Lewiecki E, Cohen S, Bolognese M, Woodson G, Moffett A . Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006; 354(8):821-31. DOI: 10.1056/NEJMoa044459. View

19.

McClung M, Lewiecki E, Geller M, Bolognese M, Peacock M, Weinstein R . Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int. 2012; 24(1):227-35. PMC: 3536967. DOI: 10.1007/s00198-012-2052-4. View

20.

Cummings S, San Martin J, McClung M, Siris E, Eastell R, Reid I . Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361(8):756-65. DOI: 10.1056/NEJMoa0809493. View